TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A modeling study estimates that replacing the universal hepatitis B vaccine birth-dose recommendation with shared decision-making could raise chronic infections in a single U.S. birth cohort by 83%, from 255 to 467 cases. The projections depend on vaccination uptake and do not model later liver disease or deaths.
A modeling study estimates that replacing the universal hepatitis B vaccine birth-dose recommendation with shared decision-making could raise chronic infections by 83% in a single U.S. birth cohort, from 255 to 467 cases. The projection comes as the Centers for Disease Control and Prevention’s vaccine advisory panel has moved away from recommending the dose for every newborn.
The study, led by Amir Mohareb of Massachusetts General Hospital and colleagues, modeled a cohort of 3.6 million U.S. infants. If the first hepatitis B vaccine dose were delayed until age 2 months, the model estimated 303 chronic infections, up from 255 under a universal birth-dose policy—a 19% increase. Under shared decision-making, it projected 467 cases.
The authors also estimated how many people could remain susceptible to infection by age 20. In the shared-decision scenario, that number reached 1,806,000, compared with 232,000 under universal birth-dose vaccination. These are model projections, not counts of observed infections, and the estimates depend on assumptions about whether families choose vaccination.
In scenarios with lower uptake, the projected burden rose further. At 75% uptake under delayed vaccination, the model estimated 357 chronic infections, 40% above the birth-dose estimate. At 26% uptake under shared decision-making, it projected 575 infections, 125% above the comparison estimate. The authors also modeled a scenario with lower birth-dose coverage among infants whose mothers were hepatitis B-positive or had unknown status, alongside higher population prevalence; in that scenario, estimates reached 1,700 infections with delayed vaccination and 2,192 with shared decision-making.
How Lower Uptake Could Change Risk
The findings matter because hepatitis B can become chronic, particularly when infection occurs around birth. The source report says 90% of newborns exposed to the virus perinatally develop chronic infection. It also cites an estimate that one in four people with untreated chronic hepatitis B will develop complications, including cirrhosis or liver cancer.
The study does not establish that infections will rise by these amounts in practice. It shows how projected outcomes change under specified vaccination strategies and uptake assumptions. The authors warn that if revised guidance leads to lower coverage, infections could exceed the study’s base-case projections. That makes the actual effect dependent in part on how parents and clinicians respond to the recommendation.
As an affiliate, we earn on qualifying purchases.
The Birth-Dose Policy Change
According to the report, the CDC’s Advisory Committee on Immunization Practices voted late in 2025 to stop recommending a universal hepatitis B birth dose, ending more than three decades of that policy. For infants whose mothers test negative for hepatitis B surface antigen, the panel recommended shared clinical decision-making: parents and clinicians decide when or whether to vaccinate. If families decline the birth dose, the panel suggested beginning at 2 months.
The proposed approach retains different guidance for high-risk groups. The study’s results are described as consistent with two other modeling studies published earlier in 2026, which also raised concerns about removing the universal dose. The source says birth-dose vaccination has been shown to be safe and effective, but the article does not provide details of those studies or the evidence considered by the advisory panel.
“These estimates suggest that the relative increase in HBV infections would be substantial, although the absolute increase would remain modest, at least in the early years after a policy change.”
— Amir Mohareb and colleagues, as quoted in the study
As an affiliate, we earn on qualifying purchases.
Limits of the Infection Projections
The estimates are projections from a model, not forecasts confirmed by future surveillance. The source does not provide the full methods or all assumptions behind the scenarios, and real-world results will depend on vaccine uptake and how the guidance is implemented. It is also unclear how clinicians and families will respond to shared decision-making.
The study did not simulate the development of liver disease or deaths. Its models also did not predict immunity levels among children who received only one or two doses of the three-dose series. The reported figures therefore do not measure the full range of possible health outcomes, and the source does not report observed post-policy infection data.
As an affiliate, we earn on qualifying purchases.
Tracking Uptake and Infections
The next meaningful evidence will come from monitoring vaccination coverage, including whether infants receive a birth dose or begin later, and from tracking hepatitis B infections over time. The source does not identify a specific next study milestone or date for new data. Until such evidence is available, the modeled totals should be read as conditional estimates rather than a confirmed increase in cases.
Policymakers and clinicians will also need to assess how the revised guidance affects vaccination among infants whose mothers test positive or have unknown hepatitis B status. The study’s alternative scenario suggests those coverage patterns, alongside population prevalence, could substantially change projected childhood infections.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study project?
For a modeled U.S. birth cohort of 3.6 million infants, it estimated 467 chronic infections under shared decision-making, compared with 255 under a universal birth-dose policy.
Does the study show that infections have already increased?
No. The numbers are model estimates, not observed case counts after the policy change. The source provides no post-policy surveillance data confirming an increase.
What does shared decision-making mean in this guidance?
For infants whose mothers test negative for hepatitis B surface antigen, parents and clinicians decide when or whether to give the vaccine. If the birth dose is declined, the panel suggested starting at 2 months.
Why might vaccination uptake affect the results?
The modeled infection totals rise when fewer infants are vaccinated. For example, the study estimated 575 chronic infections in a shared-decision scenario with 26% uptake, compared with 255 under the universal birth-dose scenario.
What outcomes did the model leave out?
The study did not simulate later liver disease or deaths, and it did not estimate immunity in children who received only one or two doses of the three-dose vaccine series.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
